Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Nov;70(5):461–468. doi: 10.1136/hrt.70.5.461

Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators.

C Houde 1, D J Bohn 1, R M Freedom 1, M Rabinovitch 1
PMCID: PMC1025360  PMID: 8260279

Abstract

OBJECTIVE--To describe the demographic and haemodynamic variables of children presenting with primary pulmonary hypertension or pulmonary hypertension appearing or persisting after surgical correction of congenital heart defects and to assess the acute effect of vasodilator drugs on their pulmonary vascular bed. DESIGN--Retrospective review. SETTING--Paediatric cardiology department and intensive care unit of a large tertiary centre. PATIENTS--Fourteen consecutive patients presenting with primary pulmonary hypertension (group 1) or pulmonary hypertension persisting or appearing late after complete surgical repair (group 2). INTERVENTION--Baseline haemodynamic measurements were taken in room air at rest and repeated in 100% oxygen. With constant monitoring of heart rate and pulmonary and systemic arterial pressures, patients were given serial intravenous, sublingual, or oral incremental doses of vasodilators (mean 4.1 trials per patient). The maximum effect of the drug was charted. MAIN OUTCOME MEASURES--A positive response to acute vasodilator tests was defined as a decrease in mean pulmonary or mean systemic arterial pressure > 15% with the mean pulmonary artery pressure not reaching the systemic level and either no change or an increase in mean systemic arterial pressure. Haemodynamic variables between groups (1 v 2, responders v non-responders, patients experiencing or not experiencing adverse effects to vasodilators) were compared by a two tailed unpaired Student's t test, and their survival curves were compared by the log rank statistic. RESULTS--Groups are small and definitive conclusions are difficult to draw, but the baseline haemodynamic assessments were not significantly different between group 1 and 2 or between responders and non-responders to vasodilators. Patients experiencing adverse effects had a higher pulmonary vascular resistance (p = 0.04) and wedge pressure (p = 0.02) than those without adverse effects. Of the vasodilators used, tolazoline, hydralazine, salbutamol, phentolamine, and phenoxybenzamine were ineffective. A positive response was seen in five of 13 patients given oxygen, in one of eight given prostacyclin, four of 12 given nifedipine, four of eight given diltiazem, one of six given captopril, and two of seven given glyceryl trinitrate. Estimates of survival of the population with primary pulmonary hypertension were 37% at one year and 12% at 2.5 years. Survival was significantly shorter in the non-responders than in the responders (p = 0.005). CONCLUSION--Children with primary pulmonary hypertension present to the cardiologist at a young age (five of eight were younger than 7 years) but with advanced pulmonary vascular disease and have a poor prognosis. 64% of group 1 and group 2 patients had a positive response to acute treatment with at least one vasodilator. Calcium channel blockers were the most effective agents. There was a positive response to drugs despite a negative response to acute treatment with oxygen. The survival of non-responders was shorter than that of the responders.

Full text

PDF
461

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barst R. J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 1986 Apr;89(4):497–503. doi: 10.1378/chest.89.4.497. [DOI] [PubMed] [Google Scholar]
  2. Calhoon J. H., Grover F. L., Gibbons W. J., Bryan C. L., Levine S. M., Bailey S. R., Nichols L., Lum C., Trinkle J. K. Single lung transplantation. Alternative indications and technique. J Thorac Cardiovasc Surg. 1991 May;101(5):816–825. [PubMed] [Google Scholar]
  3. D'Alonzo G. E., Barst R. J., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Kernis J. T. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 Sep 1;115(5):343–349. doi: 10.7326/0003-4819-115-5-343. [DOI] [PubMed] [Google Scholar]
  4. Fuster V., Steele P. M., Edwards W. D., Gersh B. J., McGoon M. D., Frye R. L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 Oct;70(4):580–587. doi: 10.1161/01.cir.70.4.580. [DOI] [PubMed] [Google Scholar]
  5. HEATH D., EDWARDS J. E. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958 Oct;18(4 Pt 1):533–547. doi: 10.1161/01.cir.18.4.533. [DOI] [PubMed] [Google Scholar]
  6. Klinke W. P., Gilbert J. A. Diazoxide in primary pulmonary hypertension. N Engl J Med. 1980 Jan 10;302(2):91–92. doi: 10.1056/NEJM198001103020204. [DOI] [PubMed] [Google Scholar]
  7. Krayenbuehl H. P., Turina J., Hess O. Left ventricular function in chronic pulmonary hypertension. Am J Cardiol. 1978 Jun;41(7):1150–1158. doi: 10.1016/0002-9149(78)90872-x. [DOI] [PubMed] [Google Scholar]
  8. Long W. A., Rubin L. J. Prostacyclin and PGE1 treatment of pulmonary hypertension. Am Rev Respir Dis. 1987 Sep;136(3):773–776. doi: 10.1164/ajrccm/136.3.773. [DOI] [PubMed] [Google Scholar]
  9. Packer M., Greenberg B., Massie B., Dash H. Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med. 1982 Jun 3;306(22):1326–1331. doi: 10.1056/NEJM198206033062203. [DOI] [PubMed] [Google Scholar]
  10. Packer M. Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension? Chest. 1989 Jun;95(6):1173–1175. doi: 10.1378/chest.95.6.1173. [DOI] [PubMed] [Google Scholar]
  11. Palevsky H. I., Long W., Crow J., Fishman A. P. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation. 1990 Dec;82(6):2018–2026. doi: 10.1161/01.cir.82.6.2018. [DOI] [PubMed] [Google Scholar]
  12. Pasque M. K., Trulock E. P., Kaiser L. R., Cooper J. D. Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up. Circulation. 1991 Dec;84(6):2275–2279. doi: 10.1161/01.cir.84.6.2275. [DOI] [PubMed] [Google Scholar]
  13. Perkin R. M., Anas N. G. Pulmonary hypertension in pediatric patients. J Pediatr. 1984 Oct;105(4):511–522. doi: 10.1016/s0022-3476(84)80413-8. [DOI] [PubMed] [Google Scholar]
  14. Rabinovitch M., Haworth S. G., Castaneda A. R., Nadas A. S., Reid L. M. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation. 1978 Dec;58(6):1107–1122. doi: 10.1161/01.cir.58.6.1107. [DOI] [PubMed] [Google Scholar]
  15. Rich S., Brundage B. H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987 Jul;76(1):135–141. doi: 10.1161/01.cir.76.1.135. [DOI] [PubMed] [Google Scholar]
  16. Rich S., Brundage B. H., Levy P. S. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation. 1985 Jun;71(6):1191–1196. doi: 10.1161/01.cir.71.6.1191. [DOI] [PubMed] [Google Scholar]
  17. Rich S., Dantzker D. R., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. [DOI] [PubMed] [Google Scholar]
  18. Rich S., Martinez J., Lam W., Levy P. S., Rosen K. M. Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response. Am Heart J. 1983 Jan;105(1):119–127. doi: 10.1016/0002-8703(83)90288-0. [DOI] [PubMed] [Google Scholar]
  19. Rich S. Primary pulmonary hypertension: modes of diagnosis and aggressive treatment with vasodilators. Mt Sinai J Med. 1990 Mar;57(2):63–74. [PubMed] [Google Scholar]
  20. Robertson B. Idiopathic pulmonary hypertension in infancy and childhood. Microangiographic and histological observations in five cases. Acta Pathol Microbiol Scand A. 1971;79(3):217–227. doi: 10.1111/j.1699-0463.1971.tb01812.x. [DOI] [PubMed] [Google Scholar]
  21. Rozkovec A., Montanes P., Oakley C. M. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 1986 May;55(5):449–458. doi: 10.1136/hrt.55.5.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rubin L. J., Mendoza J., Hood M., McGoon M., Barst R., Williams W. B., Diehl J. H., Crow J., Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990 Apr 1;112(7):485–491. doi: 10.7326/0003-4819-112-7-485. [DOI] [PubMed] [Google Scholar]
  23. Scott J. P., Higenbottam T., Wallwork J. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pract. 1990 Jun;44(6):231–234. [PubMed] [Google Scholar]
  24. Shettigar U. R., Hultgren H. N., Specter M., Martin R., Davies D. H. Primary pulmonary hypertension favorable effect of isoproterenol. N Engl J Med. 1976 Dec 16;295(25):1414–1415. doi: 10.1056/NEJM197612162952506. [DOI] [PubMed] [Google Scholar]
  25. Starnes V. A., Stinson E. B., Oyer P. E., Theodore J., Kramer M. R., Marshall S., Shumway N. E. Single lung transplantation: a new therapeutic option for patients with pulmonary hypertension. Transplant Proc. 1991 Feb;23(1 Pt 2):1209–1210. [PubMed] [Google Scholar]
  26. THILENIUS O. G., NADAS A. S., JOCKIN H. PRIMARY PULMONARY VASCULAR OBSTRUCTION IN CHILDREN. Pediatrics. 1965 Jul;36:75–87. [PubMed] [Google Scholar]
  27. Weir E. K., Rubin L. J., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Elliott C. G., Fishman A. P., Goldring R. M., Groves B. M. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis. 1989 Dec;140(6):1623–1630. doi: 10.1164/ajrccm/140.6.1623. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES